Cargando…

Interview with Dr Philip McCarthy

Philip McCarthy speaks to Roshaine Wijayatunga, Senior Editor: Oncology Philip McCarthy completed his MD at Tufts University School of Medicine, Boston, MA, USA and his Internal Medicine Residency at Yale, New Haven Hospital, New Haven, CT, USA. His Fellowship was completed at Brigham and Women’s Ho...

Descripción completa

Detalles Bibliográficos
Autor principal: McCarthy, Philip
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6171988/
https://www.ncbi.nlm.nih.gov/pubmed/30302229
http://dx.doi.org/10.2217/ijh-2017-0022
_version_ 1783360864376586240
author McCarthy, Philip
author_facet McCarthy, Philip
author_sort McCarthy, Philip
collection PubMed
description Philip McCarthy speaks to Roshaine Wijayatunga, Senior Editor: Oncology Philip McCarthy completed his MD at Tufts University School of Medicine, Boston, MA, USA and his Internal Medicine Residency at Yale, New Haven Hospital, New Haven, CT, USA. His Fellowship was completed at Brigham and Women’s Hospital and the Dana Farber Cancer Insitute, Harvard University, Boston, MA, USA. His research interests are devoted to developing novel intensive and reduced intensity allogeneic (allo) and autologous (auto) hematopoietic stem cell transplant (HSCT) approaches for the treatment of hematologic disorders, leading to improved patient outcomes and decreased toxicity. He has over 20 years of experience treating HSCT patients and directing clinical and translational HSCT research studies. He has served as chair or co-chair of several clinical trials including CALGB 100104, a Phase III clinical trial evaluating lenalidomide maintenance after auto-HSCT for multiple myeloma (MM). This study demonstrated an improved progression-free and overall survival for MM patients receiving lenalidomide maintenance therapy after auto-HSCT. The Roswell Park Comprehensive Cancer Center Blood and Marrow Transplant team has developed a systematic approach to the evaluation and treatment of HSCT patients with a specific focus on predicting and minimizing treatment-related mortality. The team participates with a core group of basic science and clinical researchers who are committed to the investigation of the complications of auto- and allo-HSCT and to the developing novel approaches to improve outcomes.
format Online
Article
Text
id pubmed-6171988
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Future Medicine Ltd
record_format MEDLINE/PubMed
spelling pubmed-61719882018-10-09 Interview with Dr Philip McCarthy McCarthy, Philip Int J Hematol Oncol Interview Philip McCarthy speaks to Roshaine Wijayatunga, Senior Editor: Oncology Philip McCarthy completed his MD at Tufts University School of Medicine, Boston, MA, USA and his Internal Medicine Residency at Yale, New Haven Hospital, New Haven, CT, USA. His Fellowship was completed at Brigham and Women’s Hospital and the Dana Farber Cancer Insitute, Harvard University, Boston, MA, USA. His research interests are devoted to developing novel intensive and reduced intensity allogeneic (allo) and autologous (auto) hematopoietic stem cell transplant (HSCT) approaches for the treatment of hematologic disorders, leading to improved patient outcomes and decreased toxicity. He has over 20 years of experience treating HSCT patients and directing clinical and translational HSCT research studies. He has served as chair or co-chair of several clinical trials including CALGB 100104, a Phase III clinical trial evaluating lenalidomide maintenance after auto-HSCT for multiple myeloma (MM). This study demonstrated an improved progression-free and overall survival for MM patients receiving lenalidomide maintenance therapy after auto-HSCT. The Roswell Park Comprehensive Cancer Center Blood and Marrow Transplant team has developed a systematic approach to the evaluation and treatment of HSCT patients with a specific focus on predicting and minimizing treatment-related mortality. The team participates with a core group of basic science and clinical researchers who are committed to the investigation of the complications of auto- and allo-HSCT and to the developing novel approaches to improve outcomes. Future Medicine Ltd 2017-12 2018-02-22 /pmc/articles/PMC6171988/ /pubmed/30302229 http://dx.doi.org/10.2217/ijh-2017-0022 Text en © 2018 Future Medicine Ltd This work is licensed under a Creative Commons Attribution 4.0 License (http://creativecommons.org/licenses/by/4.0/)
spellingShingle Interview
McCarthy, Philip
Interview with Dr Philip McCarthy
title Interview with Dr Philip McCarthy
title_full Interview with Dr Philip McCarthy
title_fullStr Interview with Dr Philip McCarthy
title_full_unstemmed Interview with Dr Philip McCarthy
title_short Interview with Dr Philip McCarthy
title_sort interview with dr philip mccarthy
topic Interview
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6171988/
https://www.ncbi.nlm.nih.gov/pubmed/30302229
http://dx.doi.org/10.2217/ijh-2017-0022
work_keys_str_mv AT mccarthyphilip interviewwithdrphilipmccarthy